Infliximab 5–10 mg/kg vs placebo
Induction of 70‐point clinical response CDAI · Patients with active Crohn's disease
Infliximab 5–10 mg/kg may leads to higher clinical response defined as improvement in the scores on the CDAI… compared with placebo (low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 4.09 [1.63, 10.25]1 study · 80 participantsLow